Clara Natoli

Citado por

	Total	Desde 2019
Citas	8922	3676
Índice h	45	30
Índice i10	140	79

920

460

230

690

19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202429 17 33 33 29 34 13 41 66 47 88 71 87 90 144 129 170 155 194 196 188 180 194 211 225 211 207 263 249 270 317 394 440 411 608 714 901 785 249

Acceso público

Ver todo

13 artículos

0 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

MICHELE DE TURSIProfessore Aggregato, Università G. D'AnnunzioDirección de correo verificada de unich.it
valentina iacobelliSapienza University of RomeDirección de correo verificada de unich.it
marcello maugeri-saccàIstituto nazionale tumori, romaDirección de correo verificada de ifo.it
Luca MoscettiAzienda Ospedaliero Universitaria Policlinico ModenaDirección de correo verificada de policlinico.mo.it
daniele santiniprofessor in general pathologyDirección de correo verificada de unicampus.it
Mauro PiantelliCeSI-Met Foundation, Chieti-Pescara University, ItalyDirección de correo verificada de unich.it
Paola Patrignani"G. d'Annunzio" University, Chieti, ItalyDirección de correo verificada de unich.it
Viviana BazanUniversity of PalermoDirección de correo verificada de usa.net
Ruggero De MariaInstitute of General Pathology, Catholic University, RomeDirección de correo verificada de unicatt.it
Antonio RussoUniversity of PalermoDirección de correo verificada de community.unipa.it
Antonio CostanzoHumanitas UniversityDirección de correo verificada de hunimed.eu
Gabriel RabinovichInstituto de Biología y Medicina Experimental, CONICET and University of Buenos Aires, ArgentinaDirección de correo verificada de ibyme.conicet.gov.ar
Franco Oreste RanellettiProfessore di Istologia, Università CattolicaDirección de correo verificada de rm.unicatt.it
ANTONIO GIORDANODirector & Professor, Sbarro Institute, Temple University ; University of SienaDirección de correo verificada de temple.edu
Alberti SaverioMedical Genetics, Department BIOMORPH, University of MessinaDirección de correo verificada de unime.it
Christian RolfoProfessor in Oncology, Head of Phase I -Early Clinical Trials Unit, Oncology, Antwerp UniversityDirección de correo verificada de uza.be
Isabella SperdutiIstituto Regina Elena, Istituto San GallicanoDirección de correo verificada de ifo.gov.it
Antonio Domenico ProcopioProfessor of General and Clinical Pathology, Università Politecnica delle Marche, Ancona, ItalyDirección de correo verificada de univpm.it
Gianfranco delle FaveProfessore di Gastroenterologia, Facoltà di Medicina, Università "La Sapienza". Roma. Italia.Dirección de correo verificada de uniroma1.it
Liborio StuppiaG d'Annunzio UniversityDirección de correo verificada de unich.it

Seguir

Clara Natoli

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT University G. D'Annunzio

Dirección de correo verificada de unich.it


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? GA Rabinovich, LG Baum, N Tinari, R Paganelli, C Natoli, FT Liu, ... Trends in immunology 23 (6), 313-320, 2002	729	2002
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. P Patrignani, MR Panara, A Greco, O Fusco, C Natoli, S Iacobelli, ... Journal of Pharmacology and Experimental Therapeutics 271 (3), 1705-1712, 1994	644	1994
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021	436	2021
Concentrations of galectin-3 in the sera of normal controls and cancer patients I Iurisci, N Tinari, C Natoli, D Angelucci, E Cianchetti, S Iacobelli Clinical cancer research 6 (4), 1389-1393, 2000	427	2000
Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties P Matarrese, O Fusco, N Tinari, C Natoli, FT Liu, ML Semeraro, W Malorni, ... International journal of cancer 85 (4), 545-554, 2000	341	2000
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019	332	2019
The secreted tumor-associated antigen 90K is a potent immune stimulator A Ullrich, I Sures, M D'Egidio, B Jallal, TJ Powell, R Herbst, A Dreps, ... Journal of Biological Chemistry 269 (28), 18401-18407, 1994	233	1994
90K (Mac-2 BP) and galectins in tumor progression and metastasis A Grassadonia, N Tinari, I Iurisci, E Piccolo, A Cumashi, P Innominato, ... Glycoconjugate journal 19, 551-556, 2002	217	2002
Galectin‐3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis P Matarrese, N Tinari, ML Semeraro, C Natoli, S Iacobelli, W Malorni FEBS letters 473 (3), 311-315, 2000	198	2000
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016	169	2016
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in … V Graziano, A Grassadonia, L Iezzi, P Vici, L Pizzuti, M Barba, A Quinzii, ... The Breast 44, 33-38, 2019	154	2019
Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015	147	2015
Prognostic value of a novel circulating serum 90K antigen in breast cancer S Iacobelli, P Sismondi, M Giai, M d'Egidio, N Tinari, C Amatetti, ... British journal of cancer 69 (1), 172-176, 1994	141	1994
Gynaecomastia with cimetidine GF Delle Fave, G Tamburrano, L De Magistris, C Natoli, ML Santoro, ... Lancet 1 (8025), 1319, 1977	134	1977
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019	109	2019
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016	106	2016
Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients M Artini, C Natoli, N Tinari, A Costanzo, R Marinelli, C Balsano, P Porcari, ... Journal of hepatology 25 (2), 212-217, 1996	105	1996
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer M Zilli, A Grassadonia, N Tinari, A Di Giacobbe, S Gildetti, J Giampietro, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1795 (1), 62-81, 2009	103	2009
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020	95	2020
Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018	87	2018

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores